HR+/HER2- Breast Cancer: Inhibiting the PI3K/AKT/mTOR Pathway
Dr Vidal expands on use of PI3K/AKT/mTOR pathway inhibitors following frontline progression, focusing on the PI3K inhibitor alpelisib for patients with PIK3CA mutations, as well as capivasertib, an AKT inhibitor in development.
Aditya Bardia Gregory Vidal Komal Jhaveri Hr Her2 Breast Cancer Cdk4 6 Inhibitors Second Line Therapies
Source: onclive.com